Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase

Richard M. Bergenstal, William V. Tamborlane, Andrew Ahmann, John B. Buse, George Dailey, Stephen N. Davis, Carol Joyce, Bruce A. Perkins, John B. Welsh, Steven M. Willi, Michael A. Wood

Research output: Contribution to journalArticle

73 Scopus citations

Abstract

OBJECTIVE - To examine the effects of crossing over from optimized multiple daily injection (MDI) therapy to sensor-augmented pump (SAP) therapy for 6 months, and the effects of 18 months' sustained use of SAP. RESEARCH DESIGN AND METHODS - The 6-month, single-crossover continuation phase of Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) provided SAP therapy to 420 subjects who completed the 1-year randomized study. The primary outcome was change in A1C in the crossover group. RESULTS - A1C values were initially lower in the continuing-SAP group than in the crossover group (7.4 vs. 8.0%, P

Original languageEnglish (US)
Pages (from-to)2403-2405
Number of pages3
JournalDiabetes Care
Volume34
Issue number11
DOIs
Publication statusPublished - Nov 2011

    Fingerprint

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., ... Wood, M. A. (2011). Sensor-augmented pump therapy for A1C reduction (STAR 3) study: Results from the 6-month continuation phase. Diabetes Care, 34(11), 2403-2405. https://doi.org/10.2337/dc11-1248